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 The gene, cox-1, is over-expressed in cultured GLC4 small cell lung cancer cells 
concurrent with the development of multi-drug resistance (MDR) as a result of the use of the 
chemotherapeutic agent used to combat the cancer, doxorubicin.  Prevention of MDR has been a 
tremendous challenge in cancer research and this research is concerned with abolishment of 
MDR as a cancer survival strategy.  RNA-mediated interference technology (RNAi) was 
employed using siRNA to decrease cox-1 expression and temporarily restore the susceptibility of 
the cells to doxorubicin.  GLC4 cells are of three types: S (sensitive cells never exposed to 
doxorubicin); ADR (MDR cells cultured in doxorubicin), and; REV (revertant cells previously 
cultured in presence of doxorubicin but no longer).  REV and ADR cells were transfected with 
cox-1 siRNA.  After 24 h, 1x10
6
cells were used for RNA isolation and 1 µg of RNA was used 
for RT-PCR to assess down-regulation of cox-1 RNA.  RT-PCR results indicated that cox-1 
RNA was down-regulated to basal levels seen before exposure to doxorubicin.  Ct values for 
GLC4/ADR and cox-1 down-regulated GLC4/ADR cells were 23 and 34, respectively.  The 
result indicated abundant levels and moderate levels of cox-1 mRNA in the ADR cells and the 
transfected ADR cells respectively.  The relative expression level of cox-1 mRNA was 33% 
higher in the non-transfected GLCR/ADR cells as compared to the transfected GLCR/ADR cells 
as shown by the curve.  Two hundred thousand cells were used for hemacytometer cell counts in 
the presence of trypan blue to assess cell viability.  cox-1 down-regulation in ADR cells resulted 
in a significantly higher percentage of non-viable cells (25.4%) as compared to its non-
transfected control (20.5%) using a Student’s t-test (*P <0.05).  Similarly, fluorescence 
microscopy confirmed that apoptosis was significantly increased in the ADR cells treated with 
doxorubicin and cox-1 siRNA simultaneously (69.4%) as compared to its non-transfected control 
(56.7%) (*= P <0.01).  A Western blot analysis performed by Fernando Cuadrado indicated that 
siRNA transfection decreased the expression of COX-1 by 66% in GLC4/ ADR cells as 
compared to the non-transfected control using densitometry.  However, no conclusive results 
were obtained using flow cytometry as the flow cytometer was incapable of analyzing the mixed 
cell population (adherent and suspension) which is a characteristic of this cell line, GLC4.  Thus, 
we have clearly demonstrated that MDR cancer cells can be altered temporarily to become 
susceptible to doxorubicin, a potentially important finding for the treatment of cancer patients. 
